Trial Outcomes & Findings for Kaiser Permanente HIV Cohort Study (NCT NCT01339403)
NCT ID: NCT01339403
Last Updated: 2015-04-03
Results Overview
Incidence rate of malignancies was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were Kaiser Permanente (KP) member from the date of HIV care initiation at that institution or January 1, 1996 for KP Northern California(KPNC) and January 1, 2000 for KP Southern California(KPSC) if in care prior to this date. Malignancies included acquired immunodeficiency syndrome (AIDS)-defining malignancies and non-AIDS defining malignancies.AIDS-defining malignancies included invasive cervical cancer,invasive non-Hodgkin's lymphoma and kaposi's sarcoma;non-AIDS defining malignancies cancers ascertained from the KP cancer registries.Overall data for non-AIDS and AIDS defining malignancies, along with individual data for AIDS-defining malignancies was reported. Incidence rate was computed as the number of events per 100,000 person-years.
COMPLETED
282368 participants
Up to Week 835
2015-04-03
Participant Flow
Participants infected and uninfected with Human Immunodeficiency Virus (HIV) were recruited and analyzed retrospectively in the Kaiser Permanente HIV registry.
Participant milestones
| Measure |
Cohort 1: HIV Infected
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Overall Study
STARTED
|
24768
|
257600
|
|
Overall Study
COMPLETED
|
24768
|
257600
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Kaiser Permanente HIV Cohort Study
Baseline characteristics by cohort
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Total
n=282368 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Customized
Less than (<) 35 years
|
6883 participants
n=99 Participants
|
76826 participants
n=107 Participants
|
83709 participants
n=206 Participants
|
|
Age, Customized
Between 35 and 39 years
|
4919 participants
n=99 Participants
|
50657 participants
n=107 Participants
|
55576 participants
n=206 Participants
|
|
Age, Customized
Between 40 and 44 years
|
4700 participants
n=99 Participants
|
47564 participants
n=107 Participants
|
52264 participants
n=206 Participants
|
|
Age, Customized
Between 45 and 49 years
|
3701 participants
n=99 Participants
|
37184 participants
n=107 Participants
|
40885 participants
n=206 Participants
|
|
Age, Customized
Between 50 and 54 years
|
2302 participants
n=99 Participants
|
22942 participants
n=107 Participants
|
25244 participants
n=206 Participants
|
|
Age, Customized
Between 55 and 59 years
|
1246 participants
n=99 Participants
|
12199 participants
n=107 Participants
|
13445 participants
n=206 Participants
|
|
Age, Customized
Between 60 and 64 years
|
613 participants
n=99 Participants
|
6154 participants
n=107 Participants
|
6767 participants
n=206 Participants
|
|
Age, Customized
Greater than (>) 65 years
|
404 participants
n=99 Participants
|
4074 participants
n=107 Participants
|
4478 participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
2306 Participants
n=99 Participants
|
24134 Participants
n=107 Participants
|
26440 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
22462 Participants
n=99 Participants
|
233466 Participants
n=107 Participants
|
255928 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Up to Week 835Population: Analysis population included all participants enrolled in the study.
Incidence rate of malignancies was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were Kaiser Permanente (KP) member from the date of HIV care initiation at that institution or January 1, 1996 for KP Northern California(KPNC) and January 1, 2000 for KP Southern California(KPSC) if in care prior to this date. Malignancies included acquired immunodeficiency syndrome (AIDS)-defining malignancies and non-AIDS defining malignancies.AIDS-defining malignancies included invasive cervical cancer,invasive non-Hodgkin's lymphoma and kaposi's sarcoma;non-AIDS defining malignancies cancers ascertained from the KP cancer registries.Overall data for non-AIDS and AIDS defining malignancies, along with individual data for AIDS-defining malignancies was reported. Incidence rate was computed as the number of events per 100,000 person-years.
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of Malignancies
Kaposi's sarcoma
|
513 malignancies per 100,000 person-years
|
3 malignancies per 100,000 person-years
|
|
Incidence Rate of Malignancies
Invasive non-Hodgkin's lymphoma
|
238 malignancies per 100,000 person-years
|
20 malignancies per 100,000 person-years
|
|
Incidence Rate of Malignancies
Invasive cervical cancer
|
25 malignancies per 100,000 person-years
|
7 malignancies per 100,000 person-years
|
|
Incidence Rate of Malignancies
Non-AIDS-defining cancer
|
633 malignancies per 100,000 person-years
|
384 malignancies per 100,000 person-years
|
|
Incidence Rate of Malignancies
AIDS-defining cancer
|
740 malignancies per 100,000 person-years
|
23 malignancies per 100,000 person-years
|
PRIMARY outcome
Timeframe: Up to Week 835Population: Analysis population included all participants enrolled in the study.
Incidence rate of cardiovascular (CVS)events including myocardial infarction (MI) and ischemia was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of Myocardial Infarction and Ischemia
|
435 CVS events per 100,000 person-years
|
313 CVS events per 100,000 person-years
|
PRIMARY outcome
Timeframe: Up to Week 835Population: Analysis population included all participants enrolled in the study.
Incidence rate of AIDS-defining opportunistic infections (OI) was calculated as the number of events divided by person-time.Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1,1996 for KPNC and January 1,2000 for KPSC if in care prior to this date.OI were those that occurred on immune-compromised participants.AIDS-defining infections included:wasting syndrome;pneumocystis jirovecii pneumonia;recurrent pneumonia;cytomegalovirus;HIV-related encephalopathy;esophageal candidiasis;mycobacterium avium complex;cryptococcosis;mycobacterium tuberculosis;progressive multifocal leukoencephalopathy;lung candidiasis;toxoplasmosis of brain;coccidiomycosis;histoplasmosis;recurrent salmonella septicemia;chronic isosporiasis;cryptosporidiosis.Incidence rate was computed as the number of events per 100,000 person-years.
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Wasting syndrome
|
1002 infections per 100,000 person-years
|
15 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Pneumocystis jirovecii pneumonia
|
760 infections per 100,000 person-years
|
2 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Recurrent pneumonia
|
640 infections per 100,000 person-years
|
74 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Cytomegalovirus
|
440 infections per 100,000 person-years
|
5 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
HIV-related Encephalopathy
|
405 infections per 100,000 person-years
|
NA infections per 100,000 person-years
No participant in this arm was evaluated for HIV-related encephalopathy, since only HIV infected participants were assessed for this infection.
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Esophageal Candidiasis
|
383 infections per 100,000 person-years
|
6 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Mycobacterium avium complex
|
259 infections per 100,000 person-years
|
3 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Cryptococcosis
|
187 infections per 100,000 person-years
|
1 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Mycobacterium tuberculosis
|
157 infections per 100,000 person-years
|
25 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Progressive multifocal leukoencephalopathy
|
78 infections per 100,000 person-years
|
0 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Lung Candidiasis
|
63 infections per 100,000 person-years
|
6 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Toxoplasmosis of brain
|
58 infections per 100,000 person-years
|
1 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Coccidiomycosis
|
9 infections per 100,000 person-years
|
1 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Histoplasmosis
|
20 infections per 100,000 person-years
|
2 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Recurrent Salmonella septicemia
|
2 infections per 100,000 person-years
|
0 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Chronic Isosporiasis
|
0 infections per 100,000 person-years
|
0 infections per 100,000 person-years
|
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Cryptosporidiosis
|
72 infections per 100,000 person-years
|
0 infections per 100,000 person-years
|
PRIMARY outcome
Timeframe: Up to Week 835Population: Analysis population included all participants enrolled in the study.
Incidence rate of liver failure was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of Liver Failure
|
492 liver failure per 100,000 person-years
|
105 liver failure per 100,000 person-years
|
PRIMARY outcome
Timeframe: Up to Week 835Population: Analysis population included all participants enrolled in the study.
Incidence rate of liver related death was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of Liver Related Death
|
202 death per 100,000 person-years
|
29 death per 100,000 person-years
|
PRIMARY outcome
Timeframe: Up to Week 835Population: Analysis population included all participants enrolled in the study.
Incidence rate of Rhabdomyolysis was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of Rhabdomyolysis
|
235 rhabdomyolysis per 100,000 person-years
|
28 rhabdomyolysis per 100,000 person-years
|
PRIMARY outcome
Timeframe: Up to Week 835Population: Analysis population included all participants enrolled in the study.
Incidence rate of all-cause mortality was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years.
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of All-Cause Mortality
|
1827 death per 100,000 person-years
|
326 death per 100,000 person-years
|
PRIMARY outcome
Timeframe: Up to Week 730Population: Analysis population included all participants enrolled in the study.
Incidence rate of viral encephalitis (VE) was calculated as the number of events divided by person-time. Only the first diagnosis of each event per participant was included. Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date. Incidence rate was computed as the number of events per 100,000 person-years. The participants with viral encephalitis were followed-up up to 31st December 2009 (730 Weeks).
Outcome measures
| Measure |
Cohort 1: HIV Infected
n=24768 Participants
Participants who were diagnosed with HIV infection and received HIV care during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
Cohort 2: HIV Uninfected
n=257600 Participants
Participants who were not diagnosed with HIV infection during January 1, 1996 through December 31, 2006 (574 weeks) with follow-up extended up to 31st December 2011 (up to 835 weeks).
|
|---|---|---|
|
Incidence Rate of Viral Encephalitis
|
30 VE per 100,000 person-years
|
2 VE per 100,000 person-years
|
Adverse Events
Cohort 1: HIV Infected
Cohort 2: HIV Uninfected
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER